Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review

    Research output: Contribution to journalLetterResearchpeer-review

  2. Physical activity and type 1 diabetes: Moving from the laboratory to the real world

    Research output: Contribution to journalEditorialResearch

  3. Determinants of sexual function and dysfunction in men and women with stroke: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  4. Clinical use of the co-formulation of insulin degludec and insulin aspart

    Research output: Contribution to journalReviewResearchpeer-review

  5. Determinants of sexual dysfunction and interventions for patients with obstructive sleep apnoea: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The incretin system is an area of great interest for the development of new therapies for the management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting patients to glycaemic goals. Furthermore, current treatment modalities are not able to prevent the continued ongoing decline in pancreatic beta-cell function and, lastly, they have a number of side effects including hypoglycaemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of pharmacological agents, which improve glucose homeostasis in a multifaceted way. Their effects include potentiation of glucose-stimulated insulin secretion, glucose-dependent inhibition of glucagon secretion and reduction in gastric emptying, appetite, food intake and body weight. Additionally, preclinical data suggest that they may preserve beta-cell mass and function. The incidence of hypoglycaemia with GLP-1 receptor agonists is low, the compounds have clinically relevant effects on body weight, and data are suggesting beneficial effects on cardiovascular risk factors. Exenatide was released in 2005 for the treatment of type 2 diabetes and liraglutide is expected to be approved by the Food and Drug Administration in US and the European Medical Agency in Europe for use in 2009. In this review, the available data on the two drugs are presented and discussed.
Original languageEnglish
JournalInternational Journal of Clinical Practice
Issue number8
Pages (from-to)1154-60
Number of pages6
Publication statusPublished - 2009

ID: 173006